The authors reported that in obese mice, daily AOD-9604 administration over 14 days produced significant reductions in body weight gain, decreases in adipose tissue mass, and increases in fat oxidation, with effect sizes comparable to those of full-length human growth hormone [1]
By directly activating the cellular machinery responsible for fat breakdown in adipocytes and enhancing receptor expression in resistant fat deposits, the peptide offers advantages for stubborn fat areas that have not responded adequately to traditional approaches

5-amino-1mq clinical trial outcomes 5-amino-1mq has a longer history of clinical investigation: Multiple completed Phase II trials in metabolic disorders Mixed results in efficacy across different patient populations Ongoing studies focusing on its potential in healthy aging and longevity Safety and tolerability comparison The safety profiles of SLU-PP-332 and 5-amino-1mq are crucial considerations in their clinical use: SLU-PP-332 Injection safety profile Generally well-tolerated in clinical trials Most common adverse events include mild gastrointestinal symptoms No significant drug-drug interactions reported to date 5-amino-1mq safety considerations Long-term safety data available from multiple studies Some reports of sleep disturbances and mild cognitive effects Potential interactions with other medications affecting NAD+ metabolism The clinical efficacy comparison between SLU-PP-332 and 5-amino-1mq reveals distinct advantages and limitations for each compound

Extrapolating beyond that requires mechanistic reasoning, not direct evidence
Combining 5-amino-1mq with lifestyle factors 5-amino-1mq enhances metabolic function but does not replace the fundamentals of body composition management